|
|
- 2018
乳腺癌内分泌治疗的相关进展
|
Abstract:
| [1] | Regan MM, Francis PA, Pagani O. Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT trials[J]. J Clin Oncol, 2016, 34(19): 2221-2231. |
| [2] | Goss PE, Ingle JN, Pritchard KI, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years[J]. N Engl J Med, 2016, 375(3): 209-219. |
| [3] | Mamounas EP, Lembersky B, Jeong JH, et al. NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor(AI)or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor-positive breast cancer[J]. J Clin Breast Cancer, 2006, 7(5): 416-421. |
| [4] | Nabholtz JM, Buzdar A, Pollak M, et al.Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group[J]. J Clin Oncol, 2000, 18(22): 3758-3767. |
| [5] | Mehta RS, Barlow WE, Albain KS, et al. Combination anastrozole and fulvestrant in metastatic breast cancer[J]. N Engl J Med, 2012, 367(5): 435-444. |
| [6] | Fribbens C, OLeary B, Kilburn L, et al. Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer[J]. J Clin Oncol, 2016, 34(25): 2961-2968. |
| [7] | Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor positive advanced breast cancer[J]. N Engl J Med, 2012, 366(6): 520-529. |
| [8] | Francis PA, Regan MM, Fleming GF, et al. Adjuvant ovarian suppression in premenopausal breast cancer[J]. N Engl J Med, 2015, 372(5): 436-446. |
| [9] | Bernhard J, Luo W, Ribi K, et al. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression(TEXT and SOFT): a combined analysis of two phase 3 randomised trials[J]. Lancet Oncol, 2015, 6(7): 848-858. |
| [10] | Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E, et al. Optimal duration of extended adjuvant endocrine therapy for early breast cancer; results of the IDEAL trial(BOOG 2006-05)[J]. J Natl Cancer Inst, 2018, 110(1). doi: 10.1093/jnci/djx134. |
| [11] | Robertson JFR, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer(FALCON): an international, randomised, double-blind, phase 3 trial[J]. Lancet, 2016, 388(10063): 2997-3005. |
| [12] | Baselga J, Im SA, Iwata H, et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer(BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2017, 18(7): 904-916. |
| [13] | Finn RS, Crown JP, Ettl J, et al. Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18[J]. Breast Cancer Res, 2016, 18(1): 67. |
| [14] | Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer[J]. N Engl J Med, 2016, 375(20): 1925-1936. |
| [15] | Rita N, Minetta CL, Douglas Y, et al. Permbrolizumab plus standard neoadjuvant therapy for high risk breast cancer: results from the I-SPY2 trial[EB/OL].[2017-ASCOAbs 506]. https://meetinglibrary.asco.org/record/153653/abstract. |
| [16] | Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial[J]. Lancet, 2013, 381(9869): 805-816. |
| [17] | Gray RG, Rea D, Handley K, et al. aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer[J]. J Clin Oncol, 2013, 31: 5. |
| [18] | Tjan-Heijnen VCG, van Hellemond IEG, Peer PGM, et al. Extended adjuvant aromatase inhibition after sequential endocrine therapy(DATA): a randomised, phase 3 trial[J]. Lancet Oncol, 2017, 18(11): 1502-1511. |
| [19] | Thürlimann B, Hess D, K？berle D, et al. Anastrozole(‘Arimidex’)versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95-a sub-study of the TARGET(Tamoxifen or ‘Arimidex’ Randomized Group Efficacy and Tolerability)trial[J]. Breast Cancer Res Treat, 2004, 85(3): 247-254. |
| [20] | Paridaens RJ, Dirix LY, Beex LV, et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group[J]. J Clin Oncol, 2008, 26: 4883-4890. |
| [21] | Early Breast Cancer Trialists Collaborative Group(EBC-TCG), Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials[J]. Lancet, 2011, 378(9793): 771-784. |
| [22] | Robertson JF, Lindemann JP, Llombart-Cussac A, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ study[J]. Breast Cancer Res Treat, 2012, 136(2): 503-511. |
| [23] | Bergh J, J？nsson PE, Lidbrink EK, et al. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer[J]. J Clin Oncol, 2012, 30(16): 1919-1925. |
| [24] | Kornblum NS, Manola J, Klein P, et al. PrECOG 0102: A randomized, double-blind, phase II trial of fulvestrant plus everolimus or placebo in post-menopausal women with hormone receptor(HR)-positive, HER2-negative metastatic breast cancer(MBC)resistant to aromatase inhibitor(AI)therapy[EB/OL].[2016 SABCS S1-02]. https://www.sabcs.org/Portals/SABCS2016/Documents/SABCS-2016-Abstracts.pdf |
| [25] | Iwata H, Im SA, Masuda N, et al. PALOMA-3: phase III trial of fulvestrant with or without palbociclib in premenopausal and postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer that progressed on prior endocrine therapy-safety and efficacy in Asian patients[J]. J Glob Oncol, 2017, 3(4): 289-303. |
| [26] | Romero D. Breast cancer: MONALEESA-2 and FALCON-PFS advantage[J]. Nat Rev Clin Oncol, 2016, 13(12): 717. |
